Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Sets New 52-Week High - Still a Buy?

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) shares hit a new 52-week high during trading on Monday . The stock traded as high as $11.67 and last traded at $11.64, with a volume of 27584 shares. The stock had previously closed at $11.39.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Fresenius SE & Co. KGaA in a research report on Monday, February 3rd.

Fresenius SE & Co. KGaA Stock Up 1.8 %

The company has a current ratio of 1.36, a quick ratio of 1.05 and a debt-to-equity ratio of 0.57. The stock has a market cap of $26.81 billion, a P/E ratio of 57.14 and a beta of 0.78. The company's 50 day moving average price is $10.86 and its two-hundred day moving average price is $9.74.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported $0.18 earnings per share for the quarter. The business had revenue of $6.01 billion during the quarter. Equities analysts forecast that Fresenius SE & Co. KGaA will post 0.79 earnings per share for the current year.

Fresenius SE & Co. KGaA Company Profile

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.